GlaxoSmithKline Seeks Variation on Authorization for Ambrisentan
December 11 2014 - 7:47AM
Dow Jones News
By Rory Gallivan
LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday that it has
submitted an application to the European Medicines Agency to widen
the uses for which its pulmonary arterial hypertension treatment
Ambrisentan can be marketed.
Glaxo said its application seeks "to extend the current
therapeutic indication to include its use in initial combination
therapy for patients with pulmonary arterial hypertension."
The application is based on the results of a study conducted
with biotechnology company Gilead Sciences Inc (GILD), Glaxo
said.
At 1205 GMT, Glaxo shares were down 4 pence, or 0.3%, at 1,382
pence, valuing the company at 67.2 billion pounds ($105.4
million).
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024